BioSpace News Archive

Schrödinger, Inc. today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees.

Renovaro Inc., a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board.

Agitated Solutions, Incorporated announced that it has been issued a Medical Device Establishment License from Health Canada for its innovative Orbis™ Microbubble Generator that simplifies and streamlines the process of saline agitation and delivery for cardiac bubble studies.

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that Immix Biopharma is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.

Nexcella today announced that it is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.

The International Cartilage Regeneration & Joint Preservation Society has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research, its new President-Elect.

GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence, advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health.

Genetic Technologies Limited announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of 1,000,000 American Depositary Shares, each representing thirty ordinary shares of the Company, at a purchase price of $2.00 per ADS.

Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year.